Clinical Trial

Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Protocol Amendment History 6 changes
notable Primary completion pushed: 2026-01-15 -> 2026-06-10 2026-08-11
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-25
critical Primary endpoint(s) modified 2026-07-25
notable Primary completion moved earlier: 2026-08-30 -> 2026-01-15 2026-07-25
minor Completion pushed: 2028-10-31 -> 2029-01-15 2026-07-25
notable Primary completion pushed: 2026-06-30 -> 2026-08-30 2026-06-25
Trial Details
NCT Number NCT06577194
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Rectal Cancer, Advanced Solid Tumor
Enrollment 35 participants
Start Date 2024-10-09
Primary Completion 2026-06-10 (estimated)
Study Completion 2029-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-10